Deutsche Bank AG lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 6.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 862,151 shares of the medical equipment provider's stock after selling 60,252 shares during the quarter. Deutsche Bank AG owned about 0.44% of Zimmer Biomet worth $97,578,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock valued at $2,609,130,000 after acquiring an additional 166,763 shares during the period. Dodge & Cox grew its position in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after purchasing an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD grew its position in Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after purchasing an additional 176,337 shares during the period. Northern Trust Corp boosted its position in Zimmer Biomet by 7.6% in the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after purchasing an additional 167,435 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Zimmer Biomet by 6.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,000,838 shares of the medical equipment provider's stock worth $211,348,000 after purchasing an additional 126,151 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have commented on ZBH shares. Morgan Stanley lowered their price objective on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. The Goldman Sachs Group cut their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Finally, JMP Securities dropped their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $111.44.
View Our Latest Research Report on ZBH
Insider Buying and Selling at Zimmer Biomet
In other news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.70% of the company's stock.
Zimmer Biomet Stock Up 1.2%
Shares of ZBH traded up $1.21 during midday trading on Wednesday, reaching $103.03. The stock had a trading volume of 1,254,277 shares, compared to its average volume of 2,089,097. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71. The company's fifty day simple moving average is $93.71 and its two-hundred day simple moving average is $99.59. The company has a market cap of $20.41 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 2.28 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the company earned $2.01 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.
Zimmer Biomet Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.
Zimmer Biomet Company Profile
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Featured Stories

Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report